Early Access — free while we kick the tires
EdgarHawk

MPM BIOVENTURES 2018, L.P.

10% Owner

10% Owner
2 filings analyzed · 2 companies · Latest 2026-01-14

Companies

Company Buys Sells Direction
Aktis Oncology, Inc. AKTS 4 0 Net buying
iTeos Therapeutics, Inc. ITOS 0 1 Net selling

Activity

January 2026
2026-01-14 Aktis Oncology, Inc. AKTS
high
Buy
1,112,777 shares
$20,029,986
Significance 8/10

10% owner MPM Bioventures 2018 L.P. buys 1,112,777 shares ($20.0M) of AKTS at $18.00 post-IPO; 5 other insiders also bought in 14 days

MPM Bioventures 2018, L.P., a 10% shareholder, deployed $20,029,986.00 to purchase 1,112,777 shares at $18.00 on 2026-01-12, four trading days after AKTS's recent listing. This transaction increased the fund's stake by 12.2% to 10,260,064 shares. The purchase price of $18.00 sits below the current market price of $20.81, establishing a modest unrealized gain on the executed tranche. Notably, this transaction occurs within a cluster pattern: 5 other insiders also bought within the past 14 days, suggesting coordinated confidence from the insider group immediately following the IPO window. The Form 4 contains a derivative-conversion notation; the full economic position may include derivative holdings not yet populated in our database, so the Table I share count alone does not represent the total position. The convergence of post-IPO insider buying across multiple participants is a material signal of support for the IPO valuation.

May 2025
high
Sell
630,191 shares
$5,079,339
Significance 6/10

Venture fund MPM Bioventures sold 630,191 ITOS shares at $8.06 on 5/13, reducing stake by 23.0% to 2.11M shares.

MPM Bioventures, a major shareholder holding 2.74M shares pre-transaction, sold 630,191 shares (630.2K shares) at $8.06, reducing its stake to 2.11M shares (-23.0%). The sale occurred at a price that is -55.9% below the 52-week high of $18.09, while the stock is up +34.3% over the prior 30 days and +7.7% over 90 days. iTeos Therapeutics remains unprofitable with net income of $-34.6M on quarterly revenue of $0.00, though annual revenue growth was +177.9%. The substantial 23% reduction in holdings by this institutional investor coincides with deteriorating valuation metrics (well below 52-week highs) and the company's persistent loss-making status, despite recent price momentum.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access